If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

New Distribution Agreement

5 Jul 2007 07:46

Marchpole Holdings PLC05 July 2007 MARCHPOLE HOLDINGS PLC ("Marchpole", "the Company" or "the Group") New Distribution Contract For Subsidiary Jean Charles de Castelbajac Marchpole Holdings plc, (LSE: MPH), the fast growing fashion brand managementgroup, is pleased to announce that its wholly-owned subsidiary Jean Charles deCastelbajac ("JCC") has signed a new distribution agreement with Coronet, amember of the Itochu Group. The Itochu Group is one of Japan's largest tradingcorporations, with Coronet distributing over 12 clothing brands including luxurylabel, Roberto Cavalli. The contract is intially for two seasons, beginning with the 2008 Spring/Summercollection, with a view to extending the relationship for a further five years.Marchpole is entering into its second agreement with the Itochu Group. In 1997 JCC received recognition as a high profile and worldwide designerthrough his design and distribution partnership with Itochu in Japan and SouthKorea. The Castelbajac brands for menswear and womenswear have since developed aloyal following in these markets. Marchpole Holdings Executive Deputy Chairman, Michael Morris said, "Thisagreement represents a further stage in the development of the Castelbajac brandin Japan, where its popularity is already well established. Existing licensingagreements with Itochu generate retail sales for Castelbajac in excess of USD 75million a year and are continuing to increase. Since the acquisition of theCastelbajac brand by Marchpole in 2004, both sales and licensing income haveshown extremely encouraging growth and we confidently expect this to continue". The Itochu Group President and Chief Executive Officer, Eizo Kobayashi said, "Weare delighted to be entering into another agreement with Jean Charles deCastelbajac to continue with the success of the Castelbajac collection in Japanand South Korea. The JCC range is already a highly sought after brand and welook forward to another long and successful relationship with Jean Charles." - ends - For further information, please contact: Bell Pottinger Corporate & Financial 020 7861 3232David Rydell/Emma Kent/Amy Rajendran Marchpole Holdings plc 020 7908 7700Michael Morris, Executive Deputy ChairmanJohn Harrison, Finance Director Note to Editors: - Marchpole Holdings plc ("Marchpole") is an international brand management group that designs, produces and sells clothing and accessories for ten globally recognised fashion labels. It operates in all of the world's main markets - UK, mainland Europe, Middle East, Asia and the USA - Its respected brands include Boateng, Emmanuel Ungaro, Ungaro Homme, Jean Charles de Castelbajac ("JCC"), Jean Charles de Castelbajac / Rossignol, Jean Charles de Castelbajac/Okaidi, Jean Charles de Castelbajac / New Era, Jean Charles de Castelbajac/Lee Cooper and Homebody and Homemummy - Marchpole is renowned for its integrated approach to brand management, taking a brand from concept to design studio to the customer interface. It is not a clothing manufacturer - The Group has grown considerably in the past four years, from a licensee with one core license (YSL menswear) - to today's international business that manages its brands across a multitude of clothing lines and accessories - Marchpole's acquisition (March 2006) of Moda America - the US licensee for leading designer Emanuel Ungaro - provided further growth opportunities in the UK and America and strengthened the Company's relationship with Ungaro - The acquisition also enabled the Company to launch the Ungaro brand, already established by Marchpole in Europe and Asia, into the US, Canada and South America. The acquisition has also enabled the Company to re-launch JCC into America. - In March 2007 Marchpole acquired 100% of Greenmark Limited, an importer and wholesaler of ladies shoes who currently supply in excess of 2.5 million pairs of shoes per annum. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Feb 202012:00 pmRNSPositive feedback from phase 2 meeting with FDA
25th Feb 20203:00 pmRNSHolding(s) in Company
21st Feb 20202:31 pmRNSHolding(s) in Company
21st Feb 20202:30 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 20204:06 pmRNSDirector and other PDMR Dealings
19th Feb 20208:00 amRNSEquity Investment
18th Feb 202011:00 amRNSPrice Monitoring Extension
13th Feb 202010:45 amRNSHolding(s) in Company
12th Feb 20204:00 pmRNSHolding(s) in Company
12th Feb 20201:00 pmRNSUpdate on Distribution
11th Feb 20203:00 pmRNSHolding(s) in Company
10th Feb 20202:06 pmRNSSecond Price Monitoring Extn
10th Feb 20202:00 pmRNSPrice Monitoring Extension
10th Feb 202012:00 pmRNSNovartis Financing; Purchase Agreement with Aspire
28th Jan 20202:05 pmRNSSecond Price Monitoring Extn
28th Jan 20202:00 pmRNSPrice Monitoring Extension
14th Jan 202012:00 pmRNSAdditional positive data from phase 2b study
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 202012:00 pmRNSMereo and Oncologie Global Licensing Agreement
6th Jan 20204:45 pmRNSHolding(s) in Company
2nd Jan 202011:05 amRNSSecond Price Monitoring Extn
2nd Jan 202011:00 amRNSPrice Monitoring Extension
31st Dec 201911:00 amRNSPrice Monitoring Extension
27th Dec 201911:05 amRNSSecond Price Monitoring Extn
27th Dec 201911:00 amRNSPrice Monitoring Extension
18th Dec 20192:22 pmRNSNotification of Major Holdings in Company
16th Dec 20192:17 pmRNSNotification of Holdings in Company
3rd Dec 20194:54 pmRNSPDMR Shareholding
27th Nov 20194:12 pmRNSDirector Shareholding
25th Nov 20195:02 pmRNSDirector Shareholding
22nd Nov 20195:09 pmRNSDirector/PDMR Shareholding
20th Nov 20192:31 pmRNSPDMR Shareholding
11th Nov 201911:05 amRNSSecond Price Monitoring Extn
11th Nov 201911:00 amRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSMereo BioPharma Phase 2b ASTEROID Study
18th Oct 20197:00 amRNSHoldings in Company
17th Oct 20192:20 pmRNSHoldings in Company
14th Oct 201912:21 pmRNSNotification of Director Dealing
7th Oct 20191:00 pmRNSFDA Fast Track Designation for Navicixizumab
4th Oct 20192:57 pmRNSPDMR Notification
2nd Oct 20193:54 pmRNSPDMR Notification
26th Sep 201912:04 pmRNSPDMR Dealing
25th Sep 201910:38 amRNSPDMR Dealing
24th Sep 20191:00 pmRNSDirector Dealing
20th Sep 20192:22 pmRNSDirector Shareholding
17th Sep 20197:00 amRNSInterim results for 6 months ended June 30, 2019
13th Sep 20193:30 pmRNSDirectors' details update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.